Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 153, Issue 2, 2010, Pages 542-548

  Delorme, Richard ^a,b,c   Betancur, Catalina ^d,e   Chaste, Pauline ^b,c   Kernéis, Solen ^f   Stopin, Astrid ^a,g   Mouren, Marie Christine ^c   Collet, Corinne ^h   Bourgeron, Thomas ^c   Leboyer, Marion ^a,g,i   Launay, Jean Marie ^h  

^a INSERM U955   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c INSTITUT PASTEUR   (France)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f Cochin Pasteur Vaccinology Center ^*  (France)

^g HENRI MONDOR HOSPITAL   (France)

^h HÔPITAL LARIBOISIÈRE   (France)

ⁱ FACULTÉ DE MÉDECINE   (France)

Author keywords

Anxiety; Dopamine; Gene; Methyltransferase; Phenotype

Indexed keywords

3 O METHYLDOPA; CATECHOL METHYLTRANSFERASE; LEVODOPA;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FEMALE; GENE; GENETICS; GENOTYPE; HUMAN; M158 GENE; MALE; METHYLATION; OBSESSIVE COMPULSIVE DISORDER; PARENT; PHENOTYPE; PRIORITY JOURNAL; RELATIVE; SAMPLE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ALLELES; ANXIETY; CATECHOL O-METHYLTRANSFERASE; CHILD; CHILD, PRESCHOOL; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PARENTS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77349123060     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31016     Document Type: Article

References (39)

1. Alsobrook JP II, Zohar AH, Leboyer M, Chabane N, Ebstein RP, Pauls DL. 2002. Association between the COMT locus and obsessive-compulsive disorder in females but not males. Am J Med Genet 114:116-120.
2. Azzam A, Mathews CA. 2003. Meta-analysis of the association between the catecholamine-O-methyl-transferase gene and obsessive-compulsive disorder. Am J Med Genet Part B 123B:64-69.
3. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. 2006.Asystematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622-632.
4. Delorme R, Goussé V, Roy I, Trandafir A, Mathieu F, Mouren-Siméoni MC, Betancur C, Leboyer M. 2007. Shared executive dysfunctions in unaffected relatives of patients with autism and obsessive-compulsive disorder. Eur Psychiatry 22:32-38.
5. Denys D, Zohar J, Westenberg HG. 2004. The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence. J Clin Psychiatry 65:11-17.
6. Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, Kolachana BS, Egan MF, Weinberger DR. 2006. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry 63:1396-1406.
7. Fisher RA. 1925. Statistical methods for research workers. Edinburg: Oliver and Boyd.
8. Freeman GH, Halton JH. 1951. Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 31:141-149.
9. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. 1989. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
10. Gothelf D, Presburger G, Zohar AH, Burg M, Nahmani A, Frydman M, Shohat M, Inbar D, Aviram-Goldring A, Yeshaya J, Steinberg T, Finkelstein Y, Frisch A, Weizman A, Apter A. 2004. Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am J Med Genet B 126B:99-105.
11. Gottesman II, Gould TD. 2003. The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry 160:636-645.
12. Grados MA, Mathews CA, Tourette Syndrome Association International Consortium for Genetics. 2008. Latent class analysis of Gilles de la Tourette syndrome using comorbidities: Clinical and genetic implications. Biol Psychiatry 64:219-225.
13. Guldberg HC, Marsden CA. 1975. Catechol-O-methyl transferase: Pharmacological aspects and physiological role. Pharmacol Rev 27:135-206.
14. Insel TR, Hamilton JA, Guttmacher LB, Murphy DL. 1983. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl) 80:231-235.
15. Kobrynski LJ, Sullivan KE. 2007. Velocardiofacial syndrome, DiGeorge syndrome: The chromosome 22q11.2 deletion syndromes. Lancet 370:1443-1452.
16. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. 1996. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250.
17. Leboyer M. 2003. Searching for alternative phenotypes in psychiatric genetics. Methods Mol Med 77:145-161.
18. Lee ES, Chen H, King J, Charlton C. 2008. The role of 3-O-methyldopa in the side effects of L-dopa. Neurochem Res 33:401-411.
19. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J. 1995. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202-4210.
20. Maxwell ME. 1992. Maxwell Family Interview for Genetic Studies (FIGS):A Manual for FIGS, Clinical Neurogenetics Branch, Intramural Research Program. Bethesda: National Institute of Mental Health.
21. Melke J, Goubran Botros H, Chaste P, Betancur C, Nygren G, Anckarsäter H, Rastam M, Ståhlberg O, Gillberg IC, Delorme R, Chabane N, Mouren-Simeoni MC, Fauchereau F, Durand CM, Chevalier F, Drouot X, Collet C, Launay JM, Leboyer M, Gillberg C, Bourgeron T. 2008. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 13:90-98.
22. Meyer-Lindenberg A, Weinberger DR. 2006. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 7:818-827.
23. Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, Mattay VS, Egan M, Weinberger DR. 2006. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 11:867-877.
24. Michotte Y, Moors M, Deleu D, Herregodts P, Ebinger G. 1987. Simultaneous determination of levodopa, carbidopa, 3-O-methyldopa and dopamine in plasma using high-performance liquid chromatography with electrochemical detection. J Pharm Biomed Anal 5:659-664.
25. Müller T, Woitalla D, Fowler B, Kuhn W. 2002. 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm 109:175-179.
26. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L. 2006. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314:1930-1933.
27. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T. 1994. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51:849-859.
28. Orvaschel H, Puig-Antich J, Chambers W, Tabrizi MA, Johnson R. 1982. Retrospective assessment of prepubertal major depression with the Kiddie-SADS-e. J Am Acad Child Psychiatry 21:392-397.
29. Pooley EC, Fineberg N, Harrison PJ. 2007. The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: Case-control study and meta-analysis. Mol Psychiatry 12:556-561.
30. Russell AJ, Mataix-Cols D, Anson M, Murphy DG. 2005. Obsessions and compulsions in Asperger syndrome and high-functioning autism. Br J Psychiatry 186:525-528.
31. Samuels J, Shugart YY, Grados MA, Willour VL, Bienvenu OJ, Greenberg BD, Knowles JA, McCracken JT, Rauch SL, Murphy DL, Wang Y, Pinto A, Fyer AJ, Piacentini J, Pauls DL, Cullen B, Rasmussen SA, Hoehn-Saric R, Valle D, Liang KY, Riddle MA, Nestadt G. 2007. Significant linkage to compulsive hoarding on chromosome 14 in families with obsessive-compulsive disorder: Results from the OCD Collaborative Genetics Study. Am J Psychiatry 164:493-499.
32. Schrag A. 2005. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 4:366-370.
33. Tsankova N, Renthal W, Kumar A, Nestler EJ. 2007. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8:355-367.
34. Weinshilboum RM, Raymond FA. 1977. Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet 29:125-135.
35. Weinshilboum RM. 2006. Pharmacogenomics: Catechol O-methyltransferase to thiopurine S-methyltransferase. Cell Mol Neurobiol 26:539-561.
36. Westenberg HG, Fineberg NA, Denys D. 2007. Neurobiology of obsessive-compulsive disorder: Serotonin and beyond. CNS Spectr 12:14-27.
37. Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, Männistö PT. 2007. Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 27:10196-10209.
38. Yücel M, Harrison BJ, Wood SJ, Fornito A, Wellard RM, Pujol J, Clarke K, Phillips ML, Kyrios M, Velakoulis D, Pantelis C. 2007. Functional and biochemical alterations of the medial frontal cortex in obsessive-compulsive disorder. Arch Gen Psychiatry 64:946-955.
39. Zürcher G, Da Prada M. 1982. Rapid and sensitive single-step radiochemical assay for catechol-O-methyltransferase. J Neurochem 38:191-195.